ArticleReviews in cardiovascular medicine2026
Enhancer of Zeste Homolog 2 Inhibition Attenuates Atrial Fibrillation Post-Myocardial Infarction Through Reduced Atrial Fibrosis.
Article in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is one of the most prevalent arrhythmias following a myocardial infarction (MI), yet the pathogenesis associated with post-MI AF remains poorly understood. Enhancer of zeste homolog 2 (EZH2), an enzyme that regulates histone modifications, has been implicated in various cardiovascular diseases; however, the role of EZH2 in the development of post-MI AF also remains unclear. Methods: MI was induced in mice by ligation of the left anterior descending coronary artery (LAD), followed by intraperitoneal administration of GSK126 or vehicle control (polyethylene glycol 300 and saline). Results: MI significantly increased the incidence and duration of AF, while electrical mapping revealed decreased conduction velocity. These changes were accompanied by increased atrial fibrosis, which was associated with upregulation of EZH2 and trimethylated histone H3 at lysine 27 (H3K27me3). In GSK126-treated mice, the incidence of AF was reduced, along with a significant decrease in H3K27me3 expression and atrial fibrosis. Conclusion: Upregulation of EZH2 is associated with post-MI AF. Pharmacological inhibition of EZH2 using GSK126 attenuates atrial fibrosis and reduces the incidence of AF. These findings suggest that EZH2 may represent a potential therapeutic candidate for post-MI AF, although further validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.